Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.54 |
| ▸ | MME | P08473 | 3/20 | 0.54 |
| ▸ | ACE | P12821 | 8/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16821240 | 0.90 | SLC1A3 (0.49) | LTA4HMMEACEANPEPECE1 | |
| SCHEMBL6830160 | 0.90 | SLC1A3 (0.49) | LTA4HMMEACEANPEPECE1 | |
| SCHEMBL6179143 | 0.89 | ALDH1A1 (0.52) | ITGB3ITGA2B | |
| SCHEMBL14542772 | 0.83 | SLC1A3 (0.43) | LTA4HMMEACEANPEPECE1 | |
| SCHEMBL12513992 | 0.83 | SLC1A3 (0.43) | LTA4HMMEACEANPEPECE1 | |
| SCHEMBL6093215 | 0.83 | ITGB3 (0.67) | ITGB3ITGA2B | |
| SCHEMBL5502396 | 0.83 | ITGB3 (0.67) | ITGB3ITGA2B | |
| SCHEMBL6668234 | 0.83 | ITGB3 (0.67) | ITGB3ITGA2B | |
| SCHEMBL29613221 | 0.83 | SLC1A3 (0.57) | LTA4HMMEACEANPEPECE1 | |
| SCHEMBL18697078 | 0.81 | SLC1A3 (0.60) | LTA4HMMEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | LTA4H 337/4885MME 212/4885ACE 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.